Shares of Valeant Pharmaceuticals tumbled on Wednesday after a research firm accused the drug company of massive fraud similar to what doomed Enron.
It's the latest controversy swirling around Valeant (VRX), a $50 billion pharmaceutical giant that's backed by hedge fund billionaire Bill Ackman. Federal prosecutors are already investigating the way Valeant prices and distributes its drugs.
Valeant plunges as report alleges Enron-like fraud - Oct. 21, 2015
No comments:
Post a Comment